Larotrectinib Monotherapy - Adult. NCCP National SACT Regimen. HSE.

Regulatory approval published by the Health Service Executive.

Citation

Larotrectinib Monotherapy - Adult, 2024, version number 3, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6788/758_V3_Larotrectinib_Therapy_Adult.pdf

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication	Statements
For the treatment of adult patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion, (i) who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and (ii) who have no satisfactory treatment options	3

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	v::NTRK1	Any solid tumor	Larotrectinib
HSE (1)	v::NTRK2	Any solid tumor	Larotrectinib
HSE (1)	v::NTRK3	Any solid tumor	Larotrectinib